Cytokinetics CEO sells 5,000 shares at $60.03; holds 363,108
Cytokinetics (CYTK) reported an insider transaction.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Cytokinetics (CYTK) reported an insider transaction. President & CEO sold 5,000 shares of common stock on 10/16/2025 at $60.03 per share. Following the sale, the reporting person beneficially owns 363,108 shares directly.
Additional indirect holdings are disclosed as 2,083 shares held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares held by The Brittany Blum 2003 Irrevocable Trust.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 5,000 | $60.03 | $300K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (2)
- F1. Shares held by The Bridget Blum 2003 Irrevocable Trust.
- F2. Shares held by The Brittany Blum 2003 Irrevocable Trust.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did CYTK report on Form 4?
Were any indirect CYTK holdings disclosed?
What is the transaction date and price for the CYTK insider sale?
What is the insider’s relationship to Cytokinetics (CYTK)?
AI-generated analysis. How Rhea-AI works. Not financial advice.